Ronald Li

Ronald Li is a distinguished biopharmaceutical executive and academic leader, currently serving as Chief Executive Officer of Medera Biopharmaceutical and Chief Scientific Officer at Sardocor. With extensive experience in the field, Ronald founded Xellera Therapeutics and has held leadership roles at Novoheart, where the company is listed on the Toronto Stock Exchange and Frankfurt Stock Exchange. Academic contributions include positions as Honorary Professor at The University of Hong Kong and member of the Court at The Hong Kong Polytechnic University. Previously, Ronald held directorships at Karolinska Institutet and the Icahn School of Medicine at Mount Sinai, and was an Associate Professor at the University of California, Davis. Educational background includes a post-doctoral fellowship at The Johns Hopkins University School of Medicine and a PhD from the University of Toronto.